Docetaxel and bevacizumab with or without trastuzumab as first-line treatment for patients with metastatic breast cancer: a meta-analysis

• Published in: European review for medical and pharmacological sciences Vol. 25; no. 17; p. 5365
• Main Authors: Sun, Z-W, Lan, X-Y, Kong, F-L, Gao, Y-Y, Li, S, Xi, Y-L
• Format: Journal Article
• Language: English
• Published: Italy 01.09.2021
• Subjects: Antineoplastic Combined Chemotherapy Protocols - administration & dosage; Bevacizumab - administration & dosage; Breast Neoplasms - drug therapy; Breast Neoplasms - pathology; Docetaxel - administration & dosage; Female; Humans; Progression-Free Survival; Receptor, ErbB-2 - metabolism; Survival Rate; Trastuzumab - administration & dosage
• ISSN: 2284-0729
• DOI: 10.26355/eurrev_202109_26643

Although bevacizumab and trastuzumab have been widely added to the standard regimen for metastatic breast cancer, the clinical outcomes remain controversial. The purpose of this study was to conduct meta-analysis to verify the clinical efficacy and safety of docetaxel and bevacizumab with or without trastuzumab as first-line treatment for patients with metastatic breast cancer (MBC). All available literature of clinical trials about docetaxel, bevacizumab, trastuzumab and metastatic breast cancer was pooled from PubMed, Embase and Cochrane library database. The meta-analysis combined the progression free survival (PFS), overall response rate (ORR) and incidence of all grades adverse events in MBC patients. Seven clinical trials were included by two reviewers. Docetaxel and bevacizumab with trastuzumab show the pooled PFS was 16.53 months (95% CI: 13.95-19.11 months), the pooled ORR was 0.75 (95% CI: 0.69-0.80) in HER2-positive MBC patients. Docetaxel and bevacizumab show that the pooled PFS was 8.49 months (95% CI: 7.80-9.18 months), the pooled ORR was 0.51(95% CI: 0.47-0.55) in HER2-negative MBC patients. Both for patients with HER2-positive and negative metastatic breast cancer, docetaxel and bevacizumab with or without trastuzumab as first-line treatment resulted in long survival, especially in terms of progression-free survival. Although the overall response rates are also significantly improved, it is still controversial based on the current evidence.